[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY30015A1 - Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones - Google Patents

Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones

Info

Publication number
UY30015A1
UY30015A1 UY30015A UY30015A UY30015A1 UY 30015 A1 UY30015 A1 UY 30015A1 UY 30015 A UY30015 A UY 30015A UY 30015 A UY30015 A UY 30015A UY 30015 A1 UY30015 A1 UY 30015A1
Authority
UY
Uruguay
Prior art keywords
biological activity
antagonist
kdr
vegf
combination
Prior art date
Application number
UY30015A
Other languages
English (en)
Inventor
David Charles Blakey
Stephen Charles Emery
Jeffrey Lester Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30015A1 publication Critical patent/UY30015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a agentes que poseen actividad antiangiogénica y son por lo tanto útiles en métodos de tratamiento de estados de enfermedad vinculados a la angiogénesis en el cuerpo de un animal o ser humano. Más específicamente la invención se refiere a una combinación de un antagonista de la actividad biológica de Angiopoyetuna-2 y un antagonista de la actividad biológica de VEGF-A y/o Kdr y/o Ft11, y a los usos de dichos antagonistas.
UY30015A 2005-12-15 2006-12-15 Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones UY30015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75055105P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
UY30015A1 true UY30015A1 (es) 2007-07-31

Family

ID=37963798

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30015A UY30015A1 (es) 2005-12-15 2006-12-15 Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones

Country Status (16)

Country Link
US (5) US20090123474A1 (es)
EP (3) EP2518083A3 (es)
JP (2) JP5179373B2 (es)
KR (1) KR101371773B1 (es)
CN (2) CN101370519B (es)
AR (1) AR058359A1 (es)
AU (2) AU2006324477A1 (es)
BR (1) BRPI0619853A2 (es)
CA (1) CA2633211A1 (es)
ES (1) ES2411505T3 (es)
NO (1) NO20082448L (es)
NZ (1) NZ569787A (es)
TW (1) TW200730191A (es)
UY (1) UY30015A1 (es)
WO (1) WO2007068895A1 (es)
ZA (1) ZA200805158B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1901754A2 (en) * 2005-07-06 2008-03-26 AstraZeneca AB Combination therapy of cancer with azd2171 and gemcitabine
AU2006324477A1 (en) * 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
PL1965801T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie AZD2171 i premetreksedu
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
CN101965406A (zh) 2008-01-03 2011-02-02 斯克里普斯研究院 通过模块识别结构域的抗体靶向
EP2247305A4 (en) * 2008-01-28 2012-11-14 Medimmune Ltd STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AU2013203517B2 (en) * 2008-10-08 2015-02-05 F. Hoffmann-La Roche Ag Bispecific anti-VEGF/anti-ANG-2 antibodies
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
KR101456326B1 (ko) 2009-04-07 2014-11-12 로슈 글리카트 아게 3가, 이중특이적 항체
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012137993A1 (en) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
MX358726B (es) * 2011-06-29 2018-09-03 Amgen Inc Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
WO2013049517A2 (en) * 2011-09-30 2013-04-04 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
MX347226B (es) 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
HK1201178A1 (en) 2011-10-13 2015-08-28 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
AU2013230750B2 (en) 2012-03-08 2018-02-01 Medimmune, Llc Methods of treatment with Angiopoietin-2 antibodies
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
JP6203838B2 (ja) 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
EP3495387B1 (en) 2012-07-13 2021-09-01 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014108854A1 (en) * 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EP2967066B1 (en) 2013-03-15 2019-10-23 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
EP3352856B1 (en) 2015-09-23 2021-08-18 Aerpio Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
IL264962B2 (en) 2016-08-23 2024-09-01 Medimmune Ltd Antibodies against VEGF-A and against ANG2 and their uses
JP6326469B2 (ja) 2016-09-21 2018-05-16 株式会社Ｓｕｂａｒｕ 車両の駆動力制御装置
CN113164597B (zh) 2018-09-24 2025-02-28 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
CN117083305A (zh) * 2021-03-25 2023-11-17 南京金斯瑞生物科技有限公司 抗体融合蛋白及其用途
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (de) 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
KR20050085971A (ko) * 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
DK0942968T3 (da) 1996-12-03 2008-06-23 Amgen Fremont Inc Fuldt humane antistoffer, der binder EGFR
DE19744531A1 (de) 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
ES2199804T3 (es) * 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
RS50249B (sr) * 2000-06-23 2009-07-15 Bayer Schering Pharma Aktiengesellschaft, Kombinacije i kompozicije koje utiču na vegf/vegf i angiopoietin/tie receptor funkcije i njihova primena (ii)
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CA2478169C (en) * 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
AU2006324477A1 (en) * 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer

Also Published As

Publication number Publication date
CN103341168A (zh) 2013-10-09
JP5179373B2 (ja) 2013-04-10
EP2518083A2 (en) 2012-10-31
HK1121674A1 (en) 2009-04-30
CN101370519A (zh) 2009-02-18
CN103341168B (zh) 2016-11-02
JP2012211155A (ja) 2012-11-01
WO2007068895A9 (en) 2008-06-12
NZ569787A (en) 2011-07-29
ES2411505T3 (es) 2013-07-05
AU2011201326B2 (en) 2012-01-12
US20120288497A1 (en) 2012-11-15
KR101371773B1 (ko) 2014-03-07
AU2011201326A1 (en) 2011-04-14
JP2009521412A (ja) 2009-06-04
EP1962903B1 (en) 2013-03-13
US20090123474A1 (en) 2009-05-14
US20140023654A1 (en) 2014-01-23
EP3168234A1 (en) 2017-05-17
NO20082448L (no) 2008-07-10
WO2007068895A1 (en) 2007-06-21
ZA200805158B (en) 2009-11-25
US20160251421A1 (en) 2016-09-01
EP2518083A3 (en) 2012-12-05
EP1962903A1 (en) 2008-09-03
CN101370519B (zh) 2013-07-24
AU2006324477A1 (en) 2007-06-21
BRPI0619853A2 (pt) 2016-08-23
TW200730191A (en) 2007-08-16
US20110097321A1 (en) 2011-04-28
KR20080073766A (ko) 2008-08-11
AR058359A1 (es) 2008-01-30
CA2633211A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
UY30015A1 (es) Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones
ECSP077894A (es) Antagonistas de npy, preparación y usos
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
BRPI0608089A2 (pt) composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
CY1106600T1 (el) Ανθεκτικη, στη φθορα συνεξωθημενη μορφη δοσολογιας που περιεχει εναν ενεργο παραγοντα και εναν ανταγωνιστικο παραγοντα και διαδικασια παρασκευης αυτης
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CR7432A (es) Amidas sustituidas activas del receptor de canabinoide-1
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
UY29093A1 (es) Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
UY31281A1 (es) Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
PA8603201A1 (es) Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
CL2012000611A1 (es) Compuesto 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2- trifluoro-etoxi)-nicotinamida, util como agente que aumenta el colesterol hdl; proceso de obtencion del compuesto; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la aterosclerosis, dislipidemia, enfermedades cardiovasculares, entre otras.
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120605